A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

By afschroeder • March 31, 2026

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2026 Mar 30:1-13. doi: 10.1080/14796694.2026.2645982. Epub ahead of print. PMID: 41910021.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, NSCLC, Publications

Related Posts

A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig[...]

Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study

Ji J, Sun CL, Dale W, Cohen HJ, Kim H, Katheria V, Baclig N, Zektser Y, Niknafs A, Margolis S, Lee C, Smith C, Sedrak[...]

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ,[...]